Etiology, endoscopic management and mortality of upper gastrointestinal bleeding in patients with cancer
Carregando...
Citações na Scopus
25
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS INC
Autores
LEONARDO, Daniel Valdivia
SATO, Cezar Fabiano Manabu
Citação
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, v.1, n.1, p.60-67, 2013
Resumo
Background: The source and outcomes of upper gastrointestinal bleeding (UGIB) in oncologic patients are poorly investigated. Objective: The study aimed to investigate these issues in a tertiary academic referral center specialized in cancer treatment. Methods: This was a retrospective study including all patients with cancer referred to endoscopy due to UGIB in 2010. Results: UGIB was confirmed in 147 (of 324 patients) referred to endoscopy for a suspected episode of GI bleeding. Tumor was the most common cause of bleeding (N = 35, 23.8%), followed by varices (N = 30, 19.7%), peptic ulcer (N = 29, 16.3%) and gastroduodenal erosions (N = 16, 10.9%). Among the 32 patients with cancer of the upper GI tract, the main causes of bleeding were cancer (N = 27, 84.4%) and peptic ulcer (N = 5, 6.3%). Forty-one patients (27.9%) presented with bleeding from the primary tumor or from a metastatic lesion, and seven received endoscopic therapy, with successful initial hemostasis in six (85.7%). Rebleeding and mortality rates were not different between endoscopically treated (N = 7) and nontreated (N = 34) patients (28.6% vs. 14.7%, p = 0.342; 43.9% vs. 44.1%, p = 0.677). Median survival was 20 days, and the overall 30-day mortality rate was 44.9%. There was no predictive factor of mortality or rebleeding. Conclusion: Tumor bleeding is the most common cause of UGIB in cancer patients. UGIB in cancer patients correlates with a high mortality rate regardless of the bleeding source. Current endoscopic treatments may not be effective in preventing rebleeding or improving survival.
Palavras-chave
Gastrointestinal hemorrhage, neoplasms, human, endoscopy, gastrointestinal
Referências
- Adler DG, 2004, GASTROINTEST ENDOSC, V60, P497
- [Anonymous], 2011, ECONOMIST
- Chen YI, 2012, GASTROINTEST ENDOSC, V75, P1278, DOI 10.1016/j.gie.2012.02.009
- Cohen M, 2007, J CLIN GASTROENTEROL, V41, P810
- Heller SJ, 2010, GASTROINTEST ENDOSC, V72, P817, DOI 10.1016/j.gie.2010.06.051
- Imbesi John J, 2005, J Support Oncol, V3, P101
- LIGHTDAL.CJ, 1974, GASTROINTEST ENDOSC, V20, P152, DOI 10.1016/S0016-5107(74)73915-3
- LOFTUS EV, 1994, MAYO CLIN PROC, V69, P736
- Mercadante S, 2004, SUPPORT CARE CANCER, V12, P95, DOI 10.1007/s00520-003-0519-8
- Muller T, 2009, AM J GASTROENTEROL, V104, P330, DOI 10.1038/ajg.2008.62
- Saude Md, SITUACAO CANC BRASIL
- Savides TJ, 1996, ENDOSCOPY, V28, P244, DOI 10.1055/s-2007-1005436
- Sung JJY, 2011, ENDOSCOPY, V43, P291, DOI 10.1055/s-0030-1256311
- Sung JJY, 2010, AM J GASTROENTEROL, V105, P84, DOI 10.1038/ajg.2009.507
- SUZUKI H, 1989, WORLD J SURG, V13, P158
- Yarris JP, 2009, EMERG MED CLIN N AM, V27, P363, DOI 10.1016/j.emc.2009.04.011
- ZIMMERMAN J, 1995, J INTERN MED, V237, P331